Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and WebcastGlobeNewsWire • Wednesday
Wall Street Analysts See a 30.14% Upside in Intra-Cellular (ITCI): Can the Stock Really Move This High?Zacks Investment Research • 07/09/24
Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?Zacks Investment Research • 06/19/24
Intra-Cellular Therapies Eyes $1.7 Billion Opportunity After Phase 3 WinInvestors Business Daily • 06/18/24
Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive DisorderGlobeNewsWire • 06/18/24
Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare ConferenceGlobeNewsWire • 06/10/24
Intra-Cellular Therapies to Present at the Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/29/24
Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual MeetingGlobeNewsWire • 05/23/24
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/07/24
Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and WebcastGlobeNewsWire • 04/30/24
Intra-Cellular Therapies: Positive MDD Data And Commercial Momentum Make It A BuySeeking Alpha • 04/30/24
Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should KnowZacks Investment Research • 04/25/24
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 04/24/24